The BCL-2 biomarker in the era of molecular diagnosis of diffuse large B-cell lymphoma
- 1 January 2007
- journal article
- editorial
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 48 (6) , 1061-1063
- https://doi.org/10.1080/10428190701420467
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?Blood, 2007
- Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative studyBlood, 2006
- BCL-6 Negatively Regulates Expression of the NF-κB1 p105/p50 SubunitThe Journal of Immunology, 2005
- Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin LymphomaThe Journal of Experimental Medicine, 2003
- The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphomaBlood, 2003
- Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)Blood, 2003
- The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- The t(14;18) Chromosome Translocations Involved in B-Cell Neoplasms Result from Mistakes in VDJ JoiningScience, 1985